Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors

Roche’s Genentech on Thursday released early-stage data on its KRAS inhibitor, divarasib, as it hopes to join Amgen and Mirati in the potential blockbuster cancer market.